Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -18,6 +18,10 @@
18	18
19	19	Alkem Laboratories has its own sales and commercial infrastructure in these markets. Alkem Laboratories is constantly looking forward to product in-licensing and out-licensing opportunities in several emerging markets. This helps it leverage its product portfolio, and sales and marketing infrastructure.
20	20
	21	+
	22	+[[image:ALKEM.jpg]]
	23	+
	24	+
21	21	== Manufacturing Facilities ==
22	22
23	23	Alkem Laboratories is a high quality focused organization. Alkem’s vision and culture of high quality obsession reflects in its operations. The company's manufacturing operations are focused on producing generics, branded generics, over-the-counter (OTC) products, Active Pharmaceutical Ingredients (APIs) and nutraceuticals. These are available in full range of dosage forms, which include, capsules, injectable and liquids. This helps in furnishing quality formulations in India as well as 50 other countries.{{footnote}}https://www.alkemlabs.com/manufacturing-facilities.php{{/footnote}}
...	...	@@ -45,8 +45,6 @@
45	45	|(% style="width:136px" %)California|(% style="width:122px" %)1|(% style="width:396px" %)Active Pharmaceutical Ingredients (APIs)
46	46	|(% style="width:136px" %)St. Louis (Missouri)|(% style="width:122px" %)1|(% style="width:396px" %)Formulations - Liquids, Nasal Sprays, Semi-solids, Solids
47	47
48		-{{putFootnotes/}}
49		-
50	50	= Industry Overview =
51	51
52	52	The global pharmaceutical industry is one of the largest and the oldest industries in the world. As per a research report by the IQVIA Institute for Human Data Science, the global pharmaceutical industry is estimated to be US$ 1.25 trillion (at invoice level) in 2019 and is expected to grow at a compounded annual growth rate (CAGR) of 3-6% over 2020-2024 to touch US$ 1.6 trillion in 2024. This growth would primarily be driven by ageing and rising population, improvements in purchasing power, access to quality healthcare by poor and middle-class families worldwide and innovation and advancement in rare and specialty diseases including biologics, nucleic acid therapies and cell therapies. However, adoption of price control policies, tightening of regulations by governments in key markets and loss of exclusivity of large brands would offset some part of this growth.{{footnote}}https://www.alkemlabs.com/pdf/annual-report/Annual_Report_2019-20-2.pdf{{/footnote}}
...	...	@@ -119,6 +119,10 @@
119	119	* Of the total allocation, around ₹ 64 billion would be for ABPMJAY, similar to last year
120	120	* The AB-PMJAY scheme will be expanded by setting up more hospitals in the tier-II and III cities under the publicprivate-partnership (PPP) route
121	121
	124	+
	125	+[[image:ALKEM1.jpg]]
	126	+
	127	+
122	122	= Business Overview =
123	123
124	124	== Indian Business ==
...	...	@@ -189,6 +189,14 @@
189	189
190	190	During the quarter, the Company filed 4 abbreviated new drug applications (ANDAs) with the US FDA and received 2 approvals (including 1 tentative approval). As on June 30, 2020, the Company filed a total of 146 ANDAs and 2 new drug applications (NDA) with the US FDA. Of these, it has received approvals for 88 ANDAs (including 13 tentative approvals) and 2 NDAs.
191	191
	198	+
	199	+**Launch of Brivaracetam in India under the brand name 'Brivasure'** {{footnote}}https://www.alkemlabs.com/pdf/press-release/2021/Launch-of-Brivaracetam-in-India-under-the-brand-name-Brivasure.pdf{{/footnote}}
	200	+
	201	+**March 15, 2021**; Alkem Laboratories Ltd. (Alkem), one of the India’s leading pharmaceutical formulation development, manufacturing, and marketing companies, announce the launch of Brivasure, an affordable anti-epileptic drug for the treatment of Epilepsy in India.
	202	+
	203	+Brivasure, Alkem’s anti-epileptic drug (AED) is a generic version of the parent molecule. Alkem has launched the drug in the market at price, Brivasure 25mg - Rs.79.50/strip, Brivasure 50mg - Rs. 148.50/strip, Brivasure 75mg - Rs. 230/strip, Brivasure 100mg - Rs. 295/strip, post patent expiry of innovator product, of Brivaracetam as on February 21, 2021. The drug has been approved by the Drugs Controller General of India (DCGI) in the adjunctive management of partial onset seizure with or without secondary generalization. The drug has exhibited faster onset of action, efficacy with favorable safety profile.
	204	+
	205	+
192	192	= References =
193	193
194	194	{{putFootnotes/}}